 |
|
INQUIRY INTO ROLE OF ANTIHYPERTENSIVE DRUGS
DONALD J. SCHISSEL, M.D.;
ERLING LARSON, M.D.
AMA Arch Intern Med. 1954;94(3):438-442.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
THE TREATMENT of essential hypertension has always been disheartening. The development, however, of the newer "antihypertensive" agents has given new hope and encouragement to patients with essential hypertension and to the physician who treats them. With the advent of these agents, it seemed worth while to study the hypertensive patients in a controlled hospital practice to determine (1) the number responding to symptomatic treatment, (2) the number requiring "antihypertensive" agents, (3) the number responding to these agents after failure to respond to symptomatic treatment, and (4) the relative effectiveness of three of these agents*—the hydrogenated ergot alkaloids (Hydergin), hydralazine (Apresoline), and hexamethonium chloride (Esomid; Hexameton).
Our previous experience with the veratrum preparations led us to exclude them in this study.
MATERIAL AND METHODS
The basis of this report is a study of all hypertensive patients admitted to a general medical and surgical hospital during an 18-month period ending July, 1953.
. . . [Full Text PDF of this Article]
Author Affiliations
DES MOINES, IOWA; DAVENPORT, IOWA
Footnotes
* The Hexamethonium chloride used in this study was supplied by Burroughs Wellcome & Company, Inc., Tuckahoe, N. Y., as Hexameton, and by Ciba Pharmaceutical Products, Inc., Summit, N. J., as Esomid. The hydralazine was supplied by Ciba Pharmaceutical Products, Inc., as Apresoline, and the hydrogenated alkaloids of ergot was supplied by Sandoz Pharmaceuticals, Division of Sandoz Chemical Works, Inc., New York, as Hydergin.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
